# The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

> **NCT03694262** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 30 (actual)

## Conditions studied

- Endometrial Cancer
- Uterine Carcinosarcoma

## Interventions

- **DRUG:** Rucaparib
- **DRUG:** Bevacizumab
- **DRUG:** Atezolizumab

## Key facts

- **NCT ID:** NCT03694262
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-19
- **Primary completion:** 2023-03-30
- **Final completion:** 2026-03-10
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-04-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03694262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03694262, "The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03694262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*